(87) found that mutations or deletions of beta-2-microglobulin (B2M) resulted in the loss of MHC I expression and impaired antigen recognition, resulting in the inability of cells to recognize tumor cells, which in turn led to drug resistance. The gene discussed is B2M; the disease is neoplasm.